Could a shot replace daily HIV pills for those with uncontrolled virus?

NCT ID NCT06694805

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 4 times

Summary

This study tests a long-acting injectable HIV medication (CAB LA + RPV LA) in people whose virus is still detectable despite taking daily oral pills. About 332 participants will either get the shots or continue standard oral therapy. The goal is to see if the injections can better suppress the virus and improve patient experience.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Birmingham, Alabama, 35222, United States
GSK Investigational Site

Los Angeles, California, 90035, United States
GSK Investigational Site

Los Angeles, California, 90036, United States
GSK Investigational Site

Los Angeles, California, 90069, United States
GSK Investigational Site

Aurora, Colorado, 80045, United States
GSK Investigational Site

Denver, Colorado, 80204, United States
GSK Investigational Site

New Haven, Connecticut, 06510, United States
GSK Investigational Site

Newark, Delaware, 19711, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20017, United States
GSK Investigational Site

Jacksonville, Florida, 32209, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Sarasota, Florida, 34237, United States
GSK Investigational Site

West Palm Beach, Florida, 33409, United States
GSK Investigational Site

Atlanta, Georgia, 30308, United States
GSK Investigational Site

Decatur, Georgia, 30033, United States
GSK Investigational Site

Macon, Georgia, 31201, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Chicago, Illinois, 60613, United States
GSK Investigational Site

Chicago, Illinois, 60637, United States
GSK Investigational Site

Baltimore, Maryland, 21201, United States
GSK Investigational Site

Baltimore, Maryland, 21287, United States
GSK Investigational Site

Boston, Massachusetts, 02115, United States
GSK Investigational Site

Berkley, Michigan, 48072, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

Newark, New Jersey, 07102, United States
GSK Investigational Site

Hawthorne, New York, 10532, United States
GSK Investigational Site

New York, New York, 10010, United States
GSK Investigational Site

New York, New York, 10032, United States
GSK Investigational Site

The Bronx, New York, 10467, United States
GSK Investigational Site

The Bronx, New York, 10468, United States
GSK Investigational Site

Greensboro, North Carolina, 27401-1209, United States
GSK Investigational Site

Cincinnati, Ohio, 45267, United States
GSK Investigational Site

Columbus, Ohio, 43210, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Seattle, Washington, 98104, United States
GSK Investigational Site

Milwaukee, Wisconsin, 53212, United States
GSK Investigational Site

Buenos Aires, 1023, Argentina
GSK Investigational Site

Buenos Aires, 1427, Argentina
GSK Investigational Site

Buenos Aires, C1425AGC, Argentina
GSK Investigational Site

Capital Federal, C1181ACH, Argentina
GSK Investigational Site

Ciudad Autonoma Buenos Aires, C1405CKC, Argentina
GSK Investigational Site

Córdoba, X5000JJS, Argentina
GSK Investigational Site

Rosario, S2000PBJ, Argentina
GSK Investigational Site

Antwerp, 2000, Belgium
GSK Investigational Site

Montreal, Quebec, H2L 4P9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

Cologne, North Rhine-Westphalia, 50674, Germany
GSK Investigational Site

Berlin, 10439, Germany
GSK Investigational Site

Cologne, 50668, Germany
GSK Investigational Site

Düsseldorf, 40225, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Bari, Italy
GSK Investigational Site

Bergamo, 24127, Italy
GSK Investigational Site

Milan, 20127, Italy
GSK Investigational Site

Milan, 20142, Italy
GSK Investigational Site

Roma, 00149, Italy
GSK Investigational Site

Porto, 4099-001, Portugal
GSK Investigational Site

Porto, 4200-319, Portugal
GSK Investigational Site

Barcelona, 08026, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Barcelona, 8017, Spain
GSK Investigational Site

Bilbao, 48013, Spain
GSK Investigational Site

Cadiz, 11510, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28020, Spain
GSK Investigational Site

Madrid, 28031, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Málaga, 29010, Spain
GSK Investigational Site

Málaga, 29530, Spain
GSK Investigational Site

Murcia, 30120, Spain
GSK Investigational Site

Palma de Mallorca, 07120, Spain
GSK Investigational Site

Sabadell Barcelona, 08208, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Vigo Pontevedra, 36312, Spain
GSK Investigational Site

Zaragoza, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.